DNA Levels in Blood Correlated with Ovarian Cancer Outcomes
By LabMedica International staff writers Posted on 04 Jan 2017 |
Image: The Biomark microfluidic system for polymerase chain reactions (Photo courtesy of Fluidigm).
The development of blood biomarkers that can be used for early detection of cancer or to measure tumor burden and response to treatment is a major goal of translational cancer studies across all cancer types.
Both tumor-derived proteins and DNA can be detected in circulating plasma and serum from cancer patients. Levels of circulating tumor DNA (ctDNA) detected in a blood test can be correlated with the size of ovarian cancers and can predict a patient's response to treatment or time to disease progression.
Scientists at the Cancer Research UK Cambridge Institute (Cambridge, UK) measured levels of ctDNA carrying mutations in the tumor protein 53 gene (TP53), which are detected in 99% of patients with high-grade serous ovarian cancer (HGSOC). They analyzed 318 blood samples from 40 HGSOC patients, taken before, during, and after standard-of-care treatment were analyzed. Computerized tomography (CT) images of the patients' tumors were collected, as well as data on the progression of their cancers.
In order to quantify ctDNA levels, patient-specific TP53 TaqMan assays were designed to target mutations identified in formalin-fixed paraffin-embedded (FFPE) tissue. Digital PCR using the Biomark microfluidic system (Fluidigm, South San Francisco, CA, USA) was used to measure ctDNA levels in cell-free DNA from plasma samples collected during courses of chemotherapy. Serum CA-125 level was routinely monitored using a two-site sandwich immunoassay on a Siemens Centaur XP auto-analyzer.
The team found the fraction of mutated TP53 in ctDNA (TP53MAF) was correlated with volume of disease as measured by CT scan and unlike CA-125 pre-treatment TP53MAF levels were also correlated with each patient's time to progression. While CA-125 took 84 days to reflect the full extent of changes after chemotherapy, changes were reflected in TP53MAF in a median of just 37 days. In patients being treated for a relapse, a decrease in TP53MAF of more than 60% was associated with a longer time to progression, while a decrease of 60% or less was associated with poor response to chemotherapy and a time to progression of less than six months.
The authors concluded that their findings have strong potential for clinical utility owing to the ease of assaying DNA in plasma and the low cost and speed of ctDNA testing. Having very early information on response would empower patients and physicians to test alternative treatment options and have high utility in trials that link biomarkers to targeted therapy. The study was published on December 20, 2016, in the journal Public Library of Science Medicine.
Related Links:
Cancer Research UK Cambridge
Fluidigm
Both tumor-derived proteins and DNA can be detected in circulating plasma and serum from cancer patients. Levels of circulating tumor DNA (ctDNA) detected in a blood test can be correlated with the size of ovarian cancers and can predict a patient's response to treatment or time to disease progression.
Scientists at the Cancer Research UK Cambridge Institute (Cambridge, UK) measured levels of ctDNA carrying mutations in the tumor protein 53 gene (TP53), which are detected in 99% of patients with high-grade serous ovarian cancer (HGSOC). They analyzed 318 blood samples from 40 HGSOC patients, taken before, during, and after standard-of-care treatment were analyzed. Computerized tomography (CT) images of the patients' tumors were collected, as well as data on the progression of their cancers.
In order to quantify ctDNA levels, patient-specific TP53 TaqMan assays were designed to target mutations identified in formalin-fixed paraffin-embedded (FFPE) tissue. Digital PCR using the Biomark microfluidic system (Fluidigm, South San Francisco, CA, USA) was used to measure ctDNA levels in cell-free DNA from plasma samples collected during courses of chemotherapy. Serum CA-125 level was routinely monitored using a two-site sandwich immunoassay on a Siemens Centaur XP auto-analyzer.
The team found the fraction of mutated TP53 in ctDNA (TP53MAF) was correlated with volume of disease as measured by CT scan and unlike CA-125 pre-treatment TP53MAF levels were also correlated with each patient's time to progression. While CA-125 took 84 days to reflect the full extent of changes after chemotherapy, changes were reflected in TP53MAF in a median of just 37 days. In patients being treated for a relapse, a decrease in TP53MAF of more than 60% was associated with a longer time to progression, while a decrease of 60% or less was associated with poor response to chemotherapy and a time to progression of less than six months.
The authors concluded that their findings have strong potential for clinical utility owing to the ease of assaying DNA in plasma and the low cost and speed of ctDNA testing. Having very early information on response would empower patients and physicians to test alternative treatment options and have high utility in trials that link biomarkers to targeted therapy. The study was published on December 20, 2016, in the journal Public Library of Science Medicine.
Related Links:
Cancer Research UK Cambridge
Fluidigm
Latest Pathology News
- New AI Tool Classifies Brain Tumors More Quickly and Accurately
- AI Integrated With Optical Imaging Technology Enables Rapid Intraoperative Diagnosis
- HPV Self-Collection Solution Improves Access to Cervical Cancer Testing
- Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
- AI Advancements Enable Leap into 3D Pathology
- New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy